Alexander Hardy is the CEO of Genentech, a biotechnology company dedicated to pursuing groundbreaking science to discover and develop medicines for people with serious and life-threatening diseases. Alexander has dedicated his career to delivering on the promise of what science can do for patients, and is motivated by the same mission as he leads Genentech, an organization of ~13,500 individuals.

Alexander was previously head of Global Product Strategy at Roche Pharmaceuticals where he led cross-functional teams to develop and launch new medicines in more than 100 countries worldwide. He has served in several key leadership and senior management positions across Genentech and Roche over the past 13 years, including heading the Asia-Pacific region, overseeing patient access services and leading commercial operations for a range of medicines and therapeutic areas — from HER2-positive cancer to influenza and neuroscience. Before joining Genentech, he held leadership positions at Novartis as head of market access for Europe, country head for Denmark and business unit head and director of strategic planning and new product development in the U.K.

He lives in the San Francisco Bay Area with his wife and three daughters.